San-Diego-based Medical Marijuana Inc. has announced that its investment company, AXIM Biotechnologies (AXIM) has entered into a service agreement with the contract research organization, QPS Netherlands BV (QPS) to begin conducting comparison studies on chewing gum made with natural cannabidiol (CBD) and synthesized THC (dronabinol).
Also known as Marinol or Syndros, dronabinol is a form of synthetic THC that currently resides in the Schedule III category in the United States.
QPS will be conducting two open-label single-dose studies followed by a randomized, double-blind study involving multiple doses. The tests will be used to gauge the bioavailability of dronabinol in MedChew, a product intended for the treatment of nausea and vomiting in cancer and AIDS patients.
“We look forward to continuing our support for AXIM as they conduct these studies and remain optimistic about the company’s future results,” said Medical Marijuana Inc. CEO Dr. Stuart Titus. “It is very important for us to be able to prove the efficacy and safety of our products and it’s great to see that two of AXIM’s developed products will be tested in these upcoming studies.”
AXIM CEO John Huellmoeller said that the agreement is an important step in their clinical development program as they are working through various trial stages so they can bring their products to suffering patients.
“We are proud to work with a well-respected company such as QPS Netherlands that shares our commitment to excellence to bring well-tested and proven drugs to market,” said Huellmoeller.
QPS will also conduct an open-label, randomized, three-period pharmacokinetic study on AXIM’s CanChew product which is designed for the treatment of symptoms of drug-related psychosis.
